IL-13 and IFN-γ secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression

Journal of Immunology

Volumn 162, Issue 12, 1999, Pages 7534-7542

  Bailer, Robert T ^a   Holloway, Alvy ^b   Sun, Junwei ^a   Margolick, Joseph B ^c   Martin, Melissa ^a   Kostman, Jay ^b   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b Philadelphia Fld Initiating Grp H   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13;

ANTIGEN SPECIFICITY; ARTICLE; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; MITOGENICITY; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN SECRETION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-13; LYMPHOCYTE ACTIVATION; RNA, MESSENGER; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; VIRAL LOAD;

EID: 0033564305     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Meyaard, L., S. A. Otto, R. R. Jonker, M. J. Mijnster, R. P. Keet, and F. Miedema. 1992. Programmed death of T cells in HIV-1 infection. Science 257:217.
2. + T cells from human immunodeficiency virus-infected persons. J. Exp. Med. 182:1759.
3. + T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med 185:55.
4. Maggi, E., M Mazzetti, A. Ravina, F. Annunziato, M. de Carli, M. P. Piccinni, R. Manetti, M. Carbonari, A. M. Pesce, G. del Prete, and S. Romagnani. 1994. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and THO cells. Science 265:244.
5. Graziosi, C., G. Pantaleo, K. R. Gantt, J. P. Fortin, J. F. Demarest, O. J. Cohen, R. P. Sekaly, and A. S. Fauci. 1994. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 265:248.
6. Emilie, D., R. Fior, L. Llorente, A. Marfaing-Koka, M. Peuchmaur, O. Devergne, B. Jarrousse, J. Wijdenes, F. Boue, and P. Galanaud. 1994. Cytokines from lymphoid organs of HIV-infected patients: production and role in the immune disequilibrium of the disease and in the development of B lymphomas. Immunol. Rev. 140:5.
7. Clerici, M., T. A. Wynn, J. A. Berzofsky, S. P. Blatt, C. W. Hendrix, A. Sher, R. L. Coffman, and G. M. Shearer. 1994. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J. Clin. Invest. 93:768.
8. Clerici, M., F. T. Hakim, D. J. Venzon, S. Blatt, C. W. Hendrix, T. A. Wynn, and G. M. Shearer. 1993. Changes in interleukin-2 and inlerleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J. Clin. Invest. 91:759.
9. Meyaard, L., E. Hovenkamp, I. P. Keet, B. Hooibrink, I. H de Jong, S. A. Otto, and F. Miedema. 1996. Single cell analysis of IL-4 and IFN-gamma production by T cells from HIV-infected individuals: decreased IFN-gamma in the presence of preserved IL-4 production. J. Immunol. 157:2712.
10. Barcellini, W., G. P. Rizzardi, C. Velati, M. O. Borghi, C. Fain, A. Lazzarin, and P. L. Meroni. 1995. In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users. AIDS 9:691.
11. Chehimi, J., S. Starr, I. Frank, A. D'Andrea, X. Ma, R. MacGregor, J. Sennelier, and G, Trinchieri. 1994. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med. 179:1361.
12. Ullum, H., A. Cozzi Lepri, K. Bendtzen, J. Victor, P. C. Gotzsche, A. N. Phillips, P. Skinhoj, and B. Klarlund Pedersen. 1997. Low production of interferon γ is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. AIDS Res. Hum. Retrovir. 13:1039.
13. Clerici, M., C. Balotta, L. Meroni, E. Ferrario, C. Riva, D. Trabattoni, A. Ridolfo, M. Villa, G. M. Shearer, M. Moroni, and M. Galli. 1996. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. AIDS Res. Hum. Retrovir. 12:1053.
14. Meroni, L., D. Trabattoni, C. Balotta, C. Riva, A. Gori, M. Moroni, M. L. Villa, M. Clerici, and M. Galli. 1996. Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. AIDS 10:23.
15. Vigano, A., C. Balotta, D. Trabattoni, A. Salvaggio, C. Riva, D. Bricalli, L. Crupi, M. C. Colombo, N. Principi, M. Galli, and M. Clerici. 1996. Virologic and immunologic markers of disease progression in pediatric HIV infection. AIDS Res. Hum. Retrovir. 12:1255.
16. Murray, H. W., B. Y. Rubin, H. Masur, and R. B. Roberts. 1984. Impaired production of lymphokines and immune (γ) interferon in the acquired immunodeficiency syndrome. N. Engl. J. Med 310:883.
17. Murray, H. W., J. K. Hillman, B. Y. Rubin, C. D. Kelly, J. L. Jacobs, L. W. Tyler, D. M. Donelly, S. M. Carriero, J. H. Godbold, and R. B. Roberts. 1985. Patients at risk for AIDS-related opportunistic infections: clinical manifestations and impaired γ interferon production. N. Engl. J. Med. 313:1504.
18. Fauci, A. S. 1996. Host factors and the pathogenesis of HIV-induced disease. Nature 384:529.
19. Weissman, D., M. Ostrowski, J. Daucher, K. Gantt, A. Blauvelt, D. Altman, L. Shen, L. Ehler, J. Hoxie, P. Grint, S. Katz, and A. Fauci. 1997. Interleukin-10 decreases HIV plasma viral load: results of a phase 1 clinical trial. In Fourth Conference on Retroviruses and Opportunistic Infections (Abstr. 37), Washington, DC.
20. Tulpule, A., B. Joshi, N. DeGuzman, B. Espina, R. Mocharnuk, O. Prakash, D. Templeton, A. Levine, and P. Gill. 1997. Interleukin-4 in the treatment of AIDS-related Kaposi's sarcoma. Ann. Oncol. 8:79.
21. de Waal Malefyt, R., C. G. Figdor, R. Huijbens, S Mohan-Peterson, B. Bennett, J. Culpepper, W. Dang, G. Zurawski, and J. E. de Vries. 1993. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes: comparison with IL-4 and modulation by IFN-γ or IL-10. J. Immunol. 151:6370.
22. Zurawski, G., and J. E. de Vries. 1994. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15:19.
23. McKenzie, G., A. Bancroft, R. Grencis, and A. McKenzie 1998. A distinct role for interleukin-13 in Th2-cell-mediated immune responses. Curr. Biol. 8:339.
24. Minty, A., S. Sebastein, A. Bensussan, D. Shire, N. Vita, A. Vyakarnam, J. Wijdenes, P. Ferrara, and D. Caput. 1997. The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. Eur. Cytokine Netw. 8:203.
25. Mosmann, T., and R. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
26. + T cells: modulation by interleukin-4 and interleukin-12. Eur. J. Immunol. 26:571.
27. + Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int. Immunol. 7:1405.
28. van der Pouw Kraan, T. C , L. C. Boeije, J. T. Troon, S. K. Rutschmann, J. Wijdenes, and L. A. Aarden. 1996. Human IL-13 production is negatively influenced by CD3 engagement: enhancement of IL-13 production by cyclosporin A. J. Immunol. 156:1818.
29. McKenzie, A. N., D. A. Li, X. Largaespada, A. Sato, A. Kaneda, S. M. Zurawski, E. L. Doyle, A. Milatovich, U. Francke, N. G. Copeland, et al. 1993. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J. Immunol. 150:5436.
30. Sun, J., R. T. Bailer, S. Suterwalla, A. Minty, J. Shull, A. Holloway, R. Anthony, J. R. Kostman, and L. J. Montaner. 1998. Restorations of antigen-presenting function and T-cell memory responses in HIV-1 infected cells in vitro by Interleukin-13. In Fifth Conference on Retroviruses and Opportunistic Infections (Abstr. 601), Chicago.
31. Marshall, J. D., S. E. Robertson, G. Trinchieri, and J. Chehimi. 1997. Priming with IL-4 and IL-13 during HIV-1 infection restores in vitro IL-12 production by mononuclear cells of HIV-infected patients. J. Immunol. 159:5705.
32. Montaner, L. J., A. G. Doyle, M. Collin, G. Herbein, P. Illei, W. James, A. Minty, D. Caput, P. Ferrara, and S. Gordon. 1993. Interleukin 13 inhibits human immunodeficiency virus type 1 production in primary blood-derived human macrophages in vitro. J. Exp. Med. 178:743.
33. Montaner, L. J., R. T. Bailer, and S. Gordon. 1997. IL-13 acts on macrophages to block the completion of reverse transcription, inhibit virus production, and reduce virus infectivity. J. Leukocyte Biol. 62:126.
34. Naif, H. M., S. Li, M. Ho-Shon, J. M. Mathijs, P. Williamson, and A. L. Cunningham. 1997. The state of maturation of monocytes into macrophages determines the effects of IL4 and IL-13 on HIV replication. J. Immunol. 158:501.
35. Denis, M., and E. Ghadirian. 1994. Interleukin 13 and interleukin 4 protect bronchoalveolar macrophages from productive infection with human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 10:795.
36. D'Andrea, A., X. Ma, M. Aste-Amezaga, C. Paganin, and G. Trinchieri. 1995. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor α production. J. Exp. Med. 181:537.
37. Zou, W., A. Dulioust, R. Fior, I. Durand-Gasselin, F. Boue, P. Galanaud, and D. Emilie. 1997. Increased T-helper-type 2 cytokine production in chronic HIV infection is due to interleukin (IL)-B rather than IL-4. AIDS 11:533.
38. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
39. Guntermann, C., R. Zheng, and K. E. Nye. 1997. The effects of CD3, CD4 and CD28 signaling on lymphocytes during human immunodeficiency virus-1 infection. Eur. J. Immunol 27:1966.
40. + T lymphocytes during HIV-1 infection. AIDS 7:245.
41. + T cells are hyporesponsive to CD28-and CD40L-mediated activation in HIV-infected subjects. Clin. Exp. Immunol. 107:440.
42. Angel, J. B., A. Kumar, K. Parato, L. G. Filion, F. Diaz-Mitoma, P. Daftarian, B, Phan, E. Sun, J. M. Leonard, and D. W. Cameron. 1998. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir and saquinavir. J. Infect. Dis. 177:898.
43. Brinchmann, J. E., J. H. Dobloug, B. H. Heger, L. L. Haaheim, M. Sannes, and T. Egeland. 1994 Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J. Infect. Dis. 169:730.
44. + T cells from HIV-infected persons. J. Immunol. 153:412.
45. Vingerhoets, J. H., G. L. Vanham, L. L. Kestens, G. G. Penne, R. L. Colebunders, M. J. Vanderbruaene, P. L. Goeman, P. L. Gigase, M. DeBoer, and J. L. Ceuppens. 1995. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8 T cells from HIV infected subjects. Clin. Exp. Immunol. 100:425.
46. Rinaldo, C., P. Piazza, Y. Z. Wang, J. Armstrong, P. Gupta, M. Ho, S. Petteway, D. Reed, D. Lyter, and L. Kingsley. 1988. HIV-1-specific production of IFN-γ and modulation by recombinant IL-2 during early HIV-1 infection. J. Immunol. 140:3389.
47. Kubin, M., M. Kamoun, and G. Trinchieri. 1994. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180:211.
48. Moretta, A., G. Pantaleo, M. Lopez-Botet, and L. Moretta. 1985. Involvement of T44 molecules in an antigen-independent pathway of T cell activation: analysis of the correlations to the T cell antigen-receptor complex. J. Exp. Med. 162:823.
49. Murphy, M., R. Louden, M. Kobayashi, and G. Trinchieri. 1986. γ Interferon and lymphotoxin, released by activated T cells, synergize to inhibit granulocyte/ monocyte colony formation. J. Exp. Med. 164:263.
50. Meylan, P. R., C. A. Spina, D. D. Richman, and R. S. Kornbluth. 1993. In vitro differentiation of monocyloid THP-1 cells affects their permissiveness for HIV strains: a model system for studying the cellular basis of HIV differential tropism. Virology 193:256.
51. Kornbluth, R. S., P. S. Oh, J. R. Munis, P. H. Cleveland, and D. D. Richman. 1989. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J. Exp. Med. 169:1137.
52. Morio, T., T. Chatila, and R. S. Geha. 1997. HIV glycoprotein gp120 inhibits TCR-CD3-mediated activation of fyn and lck. Int. Immunol. 9:53.
53. Stefanova, I., M. W. Saville, C. Peters, F. R. Cleghorn, D. Schwartz, D. J. Venzon, K. J. Weinhold, N. Jack, C. Bartholomew, W. A. Blattner, R. Yarchoan, J. B. Bolen, and I. D. Horak. 1996. HIV infection-induced post-translational modification of T cell signaling molecules associated with disease progression. J. Clin. Invest. 98:1290.
54. + T cells. J. Immunol. 158:1551.
55. Meyaard, L., H. Kuiper, S. A. Otto, K. C. Wolthers, A. W. van Lier, and F. Miedema. 1995. Evidence for intact costimulation via CD28 and CD27 molecules in hyporesponsive T cells from human immunodeficiency virus-infected individuals. Eur. J. Immunol. 25:232.
56. Kelleher, A. D., A. Carr, J. Zaunders, and D. A. Cooper. 1996. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J. Infect. Dis. 173:321.
57. Schnittman, S. M., and L. Fox. 1997. Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases. AIDS Res. Hum. Retrovir. 13:815.
58. Clerici, M., and G. Shearer. 1994. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today 15:575.
59. McKenzie, G., C. Emson, S. Bell, S. Anderson, P. Fallon, G. Zurawski, R. Murray, R. Grencis, and A. McKenzie. 1998. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 9:423.